Skip to content Skip to sidebar Skip to footer

Mesoblast (ASX:MSB) Falls 7% Despite Record US$30.3M Ryoncil Quarter- Is This the Dip to Buy?

Mesoblast Shares Fall Despite Record Sales Mesoblast (ASX: MSB) shares fell around 7% on Tuesday, trading near A$1.98, after the company reported its best-ever quarterly Ryoncil sales. Net sales for…

ByUjjwal Maheshwari

Mar 2026

Biotech Stocks Healthcare Stocks Life Sciences

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

There are plenty of ASX Biotech Targets that major pharmaceutical companies wanting to minimise the impact of the Patent Cliff could look at. For those who don't know what the patent…

ByNick Sundich

Jan 2026

Healthcare Stocks

Mesoblast (ASX:MSB) Delivers 60% Jump in Ryoncil Sales, Strengthening Commercial Momentum

Mesoblast Lifts on Ryoncil Growth Mesoblast (ASX:MSB) delivered a very strong performance this morning following a positive guidance update for Ryoncil, its cell-based therapy and the only FDA approved treatment…

ByCharlie Youlden

Dec 2025

Biotech Stocks

Mesoblast (ASX:MSB) Reaches Multi-Year High as Ryoncil Revenue Targets US$30M: Is It Still a Buy?

Commercial momentum builds as Mesoblast targets two major 2026 catalysts: Adult label expansion and Revascor BLA filing. Mesoblast (ASX: MSB) closed at A$2.91 last Friday, up 27% over the past…

ByUjjwal Maheshwari

Oct 2025

Biotech Stocks Healthcare Stocks

Mesoblast (ASX:MSB): Which direction will this rollercoaster of a $3bn biotech company go next?

Biotech company Mesoblast (ASX:MSB) is the ultimate definition of a rollercoaster company. As of October 7, 2025, it is capped at $3.2bn, which makes it the third largest 'biotech' behind…

ByNick Sundich

Dec 2024

Blue Chip Stocks Gold Stocks Healthcare Stocks Small Caps Stocks Tech Stocks Technology

Here are 6 of the best performing ASX shares in 2024! Will they maintain the momentum in 2025?

Here are 6 of the best performing ASX shares in 2024! Mesoblast (ASX:MSB) - up 527% How about this for a turnaround? This stock would've found itself in the list…

ByNick Sundich

May 2024

News

Will the RBA Cut Interest Rates in 2024 and, if So, Which Stocks Should I Buy?

The Reserve Bank of Australia (RBA) has been a focal point of economic discussions in 2024. With the cash rate at a 12-year high of 4.35%, Australians are eagerly anticipating…

ByUjjwal Maheshwari

Jan 2024

Healthcare Stocks

Revascor’s FDA approval sends the Mesoblast rollercoaster upwards

Its been a rollercoaster ride for Mesoblast (ASX:MSB) shareholders, and although its been mostly downwards, the FDA approval of Revascor sent shares in the other direction. Is this a dead…

ByUjjwal Maheshwari

the Kick-ass Multipurpose WordPress Theme

Mesoblast (ASX:MSB) Falls 7% Despite Record US$30.3M Ryoncil Quarter- Is This the Dip to Buy?

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

Mesoblast (ASX:MSB) Delivers 60% Jump in Ryoncil Sales, Strengthening Commercial Momentum

Mesoblast (ASX:MSB) Reaches Multi-Year High as Ryoncil Revenue Targets US$30M: Is It Still a Buy?

Mesoblast (ASX:MSB): Which direction will this rollercoaster of a $3bn biotech company go next?

Here are 6 of the best performing ASX shares in 2024! Will they maintain the momentum in 2025?

Will the RBA Cut Interest Rates in 2024 and, if So, Which Stocks Should I Buy?

Revascor’s FDA approval sends the Mesoblast rollercoaster upwards

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here